Toggle Menu

Press Room

For physicians: VEGF tyrosine kinase inhibitor treatment risks

02/08/2012

A recent study led by scientists at Dana-Farber Cancer Institute found an slightly increased risk of fatal side effects in certain patients treated with VEGF-tyrosine kinase inhibitors. Dr. Toni Choueiri, who led the study, explains what physicians need to know about their patients' medical histories, and how they can help educate patients about the benefits and potential risks of these therapies.

NeonCRM by Neon One